pharma · Analgesia · Postoperative Pain · HRTX
Heron Therapeutics
Heron Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 100 Regency Forest Dr, Cary, North Carolina 27518, US
- Founded
- 1983
- Employees
- 188
- Programs
- 18
- Drugs
- 17
- Patents
- 46
Heron Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Heron Therapeutics.
Heron Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Aprepitant injectable emulsion
Heron Therapeutics
COVID-19
1 trial -
B10 L-BPA Injection
Heron Therapeutics
Malignant Brain Tumors
1 trial -
B10 L-BPA Injection
Heron Therapeutics
Meningioma
1 trial -
Bupivacaine HCI without epinephrine
Heron Therapeutics
Post-Operative Pain
1 trial -
Drug: B10 L-BPA Injection
Heron Therapeutics
Head and Neck Cancer
1 trial -
GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
1 trial -
HTX-011A
Heron Therapeutics
Postoperative Pain
1 trial -
HTX-011B
Heron Therapeutics
Postoperative Pain
1 trial -
HTX-034
Heron Therapeutics
Bunions
1 trial
Frequently asked questions
How many clinical projects does Heron Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.